医学
癌症
阶段(地层学)
肿瘤科
靶向治疗
重症监护医学
化疗
免疫疗法
内科学
外科
普通外科
古生物学
生物
作者
Lei Lian,Shi Yin,Jinfeng Xiao,Junsheng Peng
出处
期刊:PubMed
日期:2024-02-25
卷期号:27 (2): 196-204
标识
DOI:10.3760/cma.j.cn441530-20231215-00221
摘要
The incidence of gastric cancer ranks fifth among malignant tumors worldwide, with the fourth highest mortality rate. A noteworthy characteristic of our country is the high prevalence of advanced-stage patients of approximately 40%. Advanced-stage gastric cancer carries an unfavorable prognosis with median survival of around one year. Diagnosis methods for advanced-stage gastric cancer (such as laparoscopic exploration, molecular profiling, and artificial intelligence) are still being continuously improved, while chemotherapy remains the primary treatment. With the rapid development of medical science, the role of surgical intervention in advanced-stage gastric cancer is becoming increasingly prominent. Therefore, as gastric tumor surgeons, we should consider how to use a combination of treatments, including surgery, chemotherapy, targeted therapy, immunotherapy, and interventional therapy, based on different pathological stages and the heterogeneity of tumors. With a multidisciplinary approach involving experts from various fields, we can collectively improve the survival rate and quality of life for advanced-stage patients. This article provides a brief overview of the current advances in the diagnosis and treatment of advanced-stage gastric cancer, and discusses therapeutic decision primarily from the perspective of surgeons.
科研通智能强力驱动
Strongly Powered by AbleSci AI